Toward hepatitis C virus elimination using artificial intelligence.
作者信息
Hur Moon Haeng, Lee Jeong-Hoon
机构信息
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2024 Apr;30(2):147-149. doi: 10.3350/cmh.2024.0135. Epub 2024 Feb 23.
Abstract
摘要
相似文献
1
Toward hepatitis C virus elimination using artificial intelligence.
Clin Mol Hepatol. 2024 Apr;30(2):147-149. doi: 10.3350/cmh.2024.0135. Epub 2024 Feb 23.
2
Correspondence on Letter regarding "Toward hepatitis C virus elimination using artificial intelligence".
Clin Mol Hepatol. 2024 Apr;30(2):274-275. doi: 10.3350/cmh.2024.0152. Epub 2024 Mar 5.
3
Curing hepatitis C virus (HCV) after organ transplantation: Increased risk of rejection following HCV elimination.
Transpl Infect Dis. 2018 Feb;20(1). doi: 10.1111/tid.12796. Epub 2017 Nov 28.
4
Quantitative changes of lipoprotein(a) in chronic hepatitis C patients achieving a sustained virological response by direct-acting antivirals.
Clin Res Hepatol Gastroenterol. 2022 Oct;46(8):102011. doi: 10.1016/j.clinre.2022.102011. Epub 2022 Aug 27.
5
Behind the Decrease of Liver Stiffness After Successful Hepatitis C Virus Eradication with Direct-Acting Antiviral Agents.
Turk J Gastroenterol. 2022 Feb;33(2):169-170. doi: 10.5152/tjg.2021.20736.
6
Hepatitis C virus therapeutics: at the end of the beginning.
Top Antivir Med. 2012 Apr-May;20(1):17-9.
7
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program.
Clin Mol Hepatol. 2024 Jan;30(1):64-79. doi: 10.3350/cmh.2023.0287. Epub 2023 Nov 21.
8
New antiviral therapies for hepatitis C.
Expert Rev Anti Infect Ther. 2004 Apr;2(2):235-43. doi: 10.1586/14787210.2.2.235.
9
[Current management of hepatitis C].
Med Monatsschr Pharm. 2015 Sep;38(9):337-44; quiz 345-6.
10
Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin.
Ann Intern Med. 2004 Jan 6;140(1):72-3. doi: 10.7326/0003-4819-140-1-200401060-00035.
引用本文的文献
1
Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on "Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis".
Clin Mol Hepatol. 2025 Jan;31(1):261-263. doi: 10.3350/cmh.2024.0795. Epub 2024 Sep 20.
2
Correspondence on Letter regarding "Toward hepatitis C virus elimination using artificial intelligence".
Clin Mol Hepatol. 2024 Apr;30(2):274-275. doi: 10.3350/cmh.2024.0152. Epub 2024 Mar 5.
本文引用的文献
1
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program.
Clin Mol Hepatol. 2024 Jan;30(1):64-79. doi: 10.3350/cmh.2023.0287. Epub 2023 Nov 21.
2
Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
Clin Infect Dis. 2023 May 25. doi: 10.1093/cid/ciad319.
3
Acute hepatitis C virus infection: clinical update and remaining challenges.
Clin Mol Hepatol. 2023 Jul;29(3):623-642. doi: 10.3350/cmh.2022.0349. Epub 2023 Feb 20.
4
Global reporting of progress towards elimination of hepatitis B and hepatitis C.
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):332-342. doi: 10.1016/S2468-1253(22)00386-7. Epub 2023 Feb 8.
5
Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series [J Hepatol 73 (2020) 1170-1218].
J Hepatol. 2023 Feb;78(2):452. doi: 10.1016/j.jhep.2022.10.006. Epub 2022 Dec 1.
6
Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: An HCV-TARGET analysis.
Hepatology. 2022 Aug;76(2):483-491. doi: 10.1002/hep.32347. Epub 2022 Feb 3.
7
Cost-effectiveness of chronic hepatitis C screening and treatment.
Clin Mol Hepatol. 2022 Apr;28(2):164-173. doi: 10.3350/cmh.2021.0193. Epub 2021 Dec 27.
8
An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
J Hepatol. 2022 Feb;76(2):311-318. doi: 10.1016/j.jhep.2021.09.025. Epub 2021 Oct 2.
9
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
Liver Int. 2021 Jun;41(6):1265-1277. doi: 10.1111/liv.14849. Epub 2021 Mar 12.
10
2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations.
J Formos Med Assoc. 2020 Jul;119(7):1135-1157. doi: 10.1016/j.jfma.2020.04.002. Epub 2020 Apr 27.
Zotero 插件